Texas Administrative Code
Title 22 - EXAMINING BOARDS
Part 9 - TEXAS MEDICAL BOARD
Chapter 198 - STANDARDS FOR USE OF INVESTIGATIONAL AGENTS
Subchapter B - INVESTIGATIONAL STEM CELL TREATMENTS FOR PATIENTS WITH CERTAIN SEVERE CHRONIC DISEASES OR TERMINAL ILLNESSES
Section 198.5 - Use of Investigational Stem Cell Treatments for Patients with Certain Severe Chronic Diseases or Terminal Illnesses
Current through Reg. 49, No. 52; December 27, 2024
(a) The Legislature recognizes the need for patient access to innovative medical treatments. At the same time, the health and welfare of Texas citizens must be protected. These goals must be carefully balanced.
(b) The purpose of this subchapter is to set out the requirements for a patient to be eligible for consideration of receiving investigational stem cell treatment and under what circumstances a certified physician may administer or provide investigational stem cell treatments. The implementation of this rule is contingent upon qualifying chronic diseases or terminal illness being defined, as set out in § 1003.052 of the Texas Health and Safety Code.
(c) This rule does not require an eligible patient to receive such treatment, but rather the statute sets the eligibility standards and the parameters under which treatment may be provided to an individual with a qualifying severe chronic disease or terminal illness.
(d) Stem cell treatments which are under investigation in a clinical trial and being administered to human participants:
(e) In order for a patient to be eligible to receive treatment with investigational stem cells, the eligible patient must: